Tired of making money for others.Doing it for myself now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
If lying generated electricity,he could power the globe.
Kelt
Now that's funny.
You don't cite any authoritative sources to back up the junk you post,but you expect "everyone else" to.
Kelt
All debunked in Federal court.Grasping at straws Scotty??????
Kelt
Whatever the size of the deal is will determine the size of the SP.Doesn't matter where the launch pad is.
Kelt
Not just a hair,he's got a whole wig up it for any real Long investor.
Kelt
Sounds about right.
Kelt
$100.00 is THE NEW BRICK WALL!!!!!
Kelt
If you're right about today,I'll owe you a bottle of your favorite adult beverage.
Kelt
You think what you want.I'll think what I want.
Kelt
Poor "widdle" shorties don't like their "widdle" boat going belly up today.
Boo Hoo Hoo
Kelt
You said it Falcon!!!
Kelt
If that's the case,I have over 2 million shares.
Kelt
Stupid is what stupid does.
Kelt
Grasping at straws I see.Laughable to say the least.
HAHAHAHAHA!!!!!!
Kelt
10Q.Apologies.
The emergence of the Phoenix is at hand.
Kelt
In my view very positive.Being that it is not inside info,it can be found if one knows what to look for and where to look.
But I choose not to share it because there are those on the SMB's who do not deserve to have it handed to them on a platter.I only share such info with my closest friends who I know will not give it out.The naysayers can go pound sand I won't give them "JACK"
Kelt
Sorry.Not true.Think whatever you want.I've shared all I'm going to.
I'm also not going to entertain "guessing games" either.
Kelt
9:09 this A.M.
Kelt
The redacted part is what I choose not to share.
Hi XXX,
From the 10-K
To continue as a going concern, we must secure additional funding to support our current operating plan in
the fiscal quarter ended March 31, 2019. The Company expects to seek to obtain additional funding through
business development activities (i.e. licensing and partnerships) and future equity issuances. There can be
no assurance as to the availability or terms upon which such financing and capital might be available.
The statement reads "in" the March 31 quarter.
As we have stated we are involved in our business development activities while moving forward towards Phase 3. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
In addition, soon we hope to start up a program we put on hold due to financing needs.
We will keep shareholders posted.
Best wishes,
Leo Ehrlich | CEO |
Innovation Pharmaceuticals Inc.
100 Cummings Center, Suite 151-B Beverly, MA 01915
http://www.iPharminc.com
Email: Leo@ipharminc.com
Correct:
As we have stated we are involved in our business development activities while moving forward towards Phase 3. In addition, soon we hope to start up a program we put on hold due to financing needs.
We will keep shareholders posted.
Best wishes,
Leo Ehrlich | CEO |
Innovation Pharmaceuticals Inc.
100 Cummings Center, Suite 151-B Beverly, MA 01915
http://www.iPharminc.com
When the party gets started:
There's also a Twisted Sister video "We're not gonna take it"
Now that's a "Cork-er"
Kelt
December 12, 2017 (GLOBE NEWSWIRE) Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the European Patent Office has granted a European patent for Brilacidin, the Company’s first-in-class defensin-mimetic, in the prevention and control of Oral Mucositis (OM). Brilacidin-OM is being developed under an FDA Fast Track designation for this indication.
The European patent supplements other Brilacidin-OM patents that have been granted in the United States, Asia (Japan, Taiwan, China), Oceania (Australia) and South Africa. All currently issued patents have an expiration date of 2032. Additional Brilacidin-OM patent applications are pending in other key markets including Russia and South Korea.
NOTE:EXP.DATE 2032
LR and others "conveniently" ignore that.
THANK YOU!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
Kelt
Wrong.It has nothing to do with the FDA B-OM EOP2 meeting minutes.
Two different "animals".
Kelt
November has 30 days,not 31 and 11/30/2019 will not occur for another 10 months.
Kelt
I'll PM you if I can on Fri.Happy Hour.
Kelt
Boy did you miss the point!! ;/
Kelt
Seems my TD app didn't mention anything about early closure today.OOPS!!!
Kelt
My Ameritrade streamer is showing 0 on the bid and ask size.Anyone else seeing that?
Kelt
You and I don't have PM feature here but if you are around on Friday during "Happy Hour" I'll PM you then if you are willing.
Thanks in advance,
Kelt
Right now the "B" deal is on the front burner.One thing at a time.
Kelt
No wonder no one follows you.
Kelt
WELCOME
PRESS RELEASES
EVENTS AND PRESENTATIONS
BLOG
EMAIL ALERTS
October 24, 2018
Innovation Pharmaceuticals Granted End-of-Phase 2 Meeting
Brilacidin
BEVERLY, MA – October 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted an End-of-Phase 2 meeting with Innovation Pharmaceuticals for its clinical development program of Brilacidin oral rinse for the prevention of Severe Oral Mucositis (SOM) in Head and Neck Cancer (HNC) patients receiving chemoradiation.
The Company’s Brilacidin oral rinse demonstrated a strong therapeutic benefit in patients receiving an aggressive chemotherapy regimen (cisplatin administered 80-100 mg/m2, every 21 days), which currently is the standard of care. In this patient population, the incidence of Severe OM was reduced to 25.0% in the modified Intent-to-Treat (mITT) population, versus 71.4% of patients on placebo. In the Per Protocol (PP) patient group, incidence of Severe OM dropped to 14.3% for patients receiving Brilacidin-OM, compared to 72.7% among those receiving placebo.
The completed Phase 2 study met its primary endpoint, showing a reduction of Severe OM incidence versus placebo, as well as beneficial treatment effects in reducing the duration of Severe OM and in delaying the onset of Severe OM.
Linked below is information, published in a blog on the Company’s website, elaborating on how Brilacidin is positioned compared to other investigational Oral Mucositis drugs currently in clinical development.
http://www.ipharminc.com/new-blog/2018/9/24/brilacidin-for-oral-mucositis-at-a-glance-comparative-data-presentation-with-other-investigational-om-drugs
About Brilacidin and Severe Oral Mucositis
There currently are no FDA-approved drugs for the prevention of SOM (WHO Grade ≥ 3) in HNC patients receiving chemoradiation. The additional expenses incurred by patients suffering from SOM are estimated to be as high as $18,000 to $25,000 per case in the U.S. when hospitalization is required. These factors contribute to SOM qualifying as an area of significant unmet medical need. According to published statistics, the number of new annual HNC cases in the U.S. is estimated to be 65,000, and worldwide, ~750,000 cases. Between 60 and 70 percent of these HNC patients typically will develop SOM, with the overall incidence of HNC patients developing some grade of OM (WHO Grades 1 to 4) approaching 100 percent.
From what I find,Level 4 is focused on options trading and therefore would have no purpose here.
More BS,maybe he has level 10 too!
Kelt
Daubers,can you please PM me at my home base.Thanks,Kelt
Not much DD being shared here today but at least a few of you are calling a spade a spade.
I'll go back to my other board haunts now.
Kelt
I received confirmation of my opinions about the invite and expenses re: yesterday's IBD PR.from Leo today.
Also shared some great insights from Pete as well.
Kelt